Research Paper Volume 15, Issue 24 pp 15473—15488
Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study
Figure 4. Swimmer plot of the patients receiving Disitamab Vedotin alone and combined with ICI (A). Swimmer plot of the patients with different expression levels of HER2 (B). Swimmer plot of the patients with urinary cancer and other cancers (C).